Overview
Advances in the Multidisciplinary Management of Hepatocellular Carcinoma (HCC): Strategies for Incorporating Emerging Immunotherapy Treatment Options
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Expert faculty Richard Finn, MD, discusses treatment options and strategies in a case-based approach for two patients who have failed conventional therapies and may be candidates for immunotherapy. The activity features an online platform that affords clinicians an opportunity to absorb relevant clinical and evidence-based information.
This activity is intended for physicians (oncologists, interventional radiologists, hepatologists), and other clinicians, who care for patients with hepatocellular carcinoma.
To inform clinicians on integrating immunotherapy into treatment options of advanced hepatocellular carcinoma patients through a case-based discussion of those patients who have failed conventional therapies, and may be candidates for approved or emerging immunotherapeutic agents.
Upon completion of this activity, participants will be able to:
• Differentiate the mechanisms of action and scientific rationale of currently available systemic therapies with the use of immunotherapy approaches in advanced HCC
• Discuss the role of new and emerging immunotherapies in current treatment paradigms for advanced HCC
• Review the efficacy, safety and tolerability of emerging agents for advanced HCC and the management of immune-related adverse events
• Evaluate the evolving immunotherapeutic research landscape, including ongoing studies in earlier stages of disease as well as personalized and locoregional therapies
• Differentiate the mechanisms of action and scientific rationale of currently available systemic therapies with the use of immunotherapy approaches in advanced HCC
• Discuss the role of new and emerging immunotherapies in current treatment paradigms for advanced HCC
• Review the efficacy, safety and tolerability of emerging agents for advanced HCC and the management of immune-related adverse events
• Evaluate the evolving immunotherapeutic research landscape, including ongoing studies in earlier stages of disease as well as personalized and locoregional therapies
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 11.0 or higher, Safari 10.0 or higher and Firefox 55.0 or higher
4. Use Adobe Reader to print certificate.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 11.0 or higher, Safari 10.0 or higher and Firefox 55.0 or higher
4. Use Adobe Reader to print certificate.
Richard S. Finn, MD
Associate Professor of Medicine
Medicine, Division of Hematology/Oncology
Geffen School of Medicine at UCLA
Los Angeles, CA
Associate Professor of Medicine
Medicine, Division of Hematology/Oncology
Geffen School of Medicine at UCLA
Los Angeles, CA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Richard Finn, MD (Faculty)
Consulting Agreements: Bayer, Bristol-Myers Squibb, Eisai, Merck & Co., Pfizer, Eli Lilly
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Lenvatinib, Pembrolizimab
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 50% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.